NEW YORK (360Dx) – Roche said today that the US Food and Drug Administration has approved its Ventana ALK (D5F3) companion diagnostic as an aid in identifying ALK-positive non-small cell lung cancer patients who would benefit from treatment with the firm's drug Alecensa (alectinib).
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.